2006
DOI: 10.1158/0008-5472.can-05-3906
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Most gastrointestinal stromal tumors (GISTs) possess a gainof-function mutation in c-KIT. Imatinib mesylate, a smallmolecule inhibitor against several receptor tyrosine kinases, including KIT, platelet-derived growth factor receptor-A, and BCR-ABL, has therapeutic benefit for GISTs both via KIT and via unknown mechanisms. Clinical evidence suggests that a potential therapeutic benefit of imatinib might result from decreased glucose uptake as measured by positron emission tomography using 18-fluoro-2-deoxy-D-gl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

6
54
0

Year Published

2007
2007
2017
2017

Publication Types

Select...
4
4

Relationship

1
7

Authors

Journals

citations
Cited by 69 publications
(60 citation statements)
references
References 53 publications
6
54
0
Order By: Relevance
“…The GIST882 tumor cell line possessing a homozygous mutation in KIT exon 13, the GIST-T1/829 subline derived from parental GIST-T1 cells possessing a secondary A829P kinase domain mutation, and the GIST430 tumor cell line possessing a primary KIT exon 11 deletion with a secondary mutation (V654A substitution), were all generously provided by Jonathan A. Fletcher (20). Cells were grown as described in (11) (GIST-T1), (21) (GIST882) and (20) (GIST-T1/829 and GIST430) and were routinely (last tested April 2016) monitored by Sanger sequencing to confirm their KIT mutation status and cell line identity. Imatinib mesylate (IM) (Gleevec™) was obtained from the Fox Chase Cancer Center (FCCC) Pharmacy, dissolved in sterile PBS and stored at −20°C.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…The GIST882 tumor cell line possessing a homozygous mutation in KIT exon 13, the GIST-T1/829 subline derived from parental GIST-T1 cells possessing a secondary A829P kinase domain mutation, and the GIST430 tumor cell line possessing a primary KIT exon 11 deletion with a secondary mutation (V654A substitution), were all generously provided by Jonathan A. Fletcher (20). Cells were grown as described in (11) (GIST-T1), (21) (GIST882) and (20) (GIST-T1/829 and GIST430) and were routinely (last tested April 2016) monitored by Sanger sequencing to confirm their KIT mutation status and cell line identity. Imatinib mesylate (IM) (Gleevec™) was obtained from the Fox Chase Cancer Center (FCCC) Pharmacy, dissolved in sterile PBS and stored at −20°C.…”
Section: Methodsmentioning
confidence: 99%
“…The whole cell extracts (WCE) were prepared and evaluated by immunoblot as described previously (11). …”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Mitochondria and telomerase are also targets of IM (4,5). IM was primarily designed to treat chronic myelogenous leukemia (CML), and is currently the drug of choice for metastatic gastrointestinal stromal tumors (6,7). The success of this compound in treating CML has led to broader studies of its application in treating other tumors, such as glioblastoma (GBM), small lung cancer, anaplastic thyroid cancer and prostate cancer (8)(9)(10)(11).…”
Section: Introductionmentioning
confidence: 99%
“…It has been reported that mitochondria and telomerase are also targets of imatinib mesylate (4,5). IM was primarily designed to treat chronic myeloid leukemia (CML), but it is also currently the drug of choice for the treatment of metastatic gastrointestinal stromal tumors (GISTs) (6,7). The success of this compound in the treatment of CML and GISTs has led to the broader examination of its application in the treatment of other tumors, such as glioblastoma (8), small lung cancer (9), anaplastic thyroid cancer (10) and prostate cancer (11).…”
Section: Introductionmentioning
confidence: 99%